Emilia Muncan

Emilia Muncan

Auto-generated profile, based on publicly available information

Emilia Muncan

Department of Clinical Neuroscience, Institute of Neuroscience and Physiology at the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2025 in World Neurosurgery
Verified
Journal Article
Open access
MAModar Alhamdan
Modar Alhamdan
ACAlba Corell
Alba Corell
KHKlas Holmgren
Klas Holmgren
EMEmilia Muncan
Emilia Muncan
PLPeter Lindvall
Peter Lindvall
TWTeodor Svedung Wettervik
Teodor Svedung Wettervik
Malignant middle cerebral artery infarction (MMI) can cause life-threatening edema with high mortality rates. Randomized controlled trials (RCTs) have shown that decompressive hemicraniectomy (DC) can improve survival rate and functional outcome in selected MMI patients. However, real-world outcomes are less well described. To investigate DC indications, timing, and outcomes in MMI patients treated at 4 Swedish neurosurgical centers and the degree of alignment of real-world patient selection with eligibility criteria from 2 landmark RCTs-DESTINY I & II. This retrospective, Swedish multicenter (n = 4) cohort study included 335 MMI patients treated with DC between 2008 and 2022. Demographics, clinical and radiological status, surgical factors, and 6-month outcomes (modified Rankin Scale [mRS]) were collected and compared across centers and with DESTINY trials. Median age was 55 (48-61) years, and 75% were male. Pre-DC, median Glasgow Coma Scale Motor score was 5 (5-6) and Charlson Comorbidity Index score was 3 (3-4). DC was performed at a median of 38 (25-56) hours from stroke onset. Median mRS at 6 months was 4 (4-5), 24% had mRS ≤ 3, and mortality was 17%. Only 19% and 12% of patients would have qualified for DESTINY I and II trials, respectively. Indication and timing of DC as a treatment of MMI demonstrated notable discrepancies in surgical practice across centers and compared to landmark RCTs. However, despite differences in timing and indications for DC, the outcome did not differ significantly across centers. Our findings provide insight into the outcome of DC performed for MMI outside the strict criteria supported by level 1 evidence.

27 March 2026 in World Neurosurgery
Verified
Journal Article
Open access
MAModar Alhamdan
Modar Alhamdan
ACAlba Corell
Alba Corell
KHKlas Holmgren
Klas Holmgren
EMEmilia Muncan
Emilia Muncan
PLPeter Lindvall
Peter Lindvall
TWTeodor Svedung Wettervik
Teodor Svedung Wettervik
Malignant middle cerebral artery infarction (MMI) is a severe condition caused by space-occupying brain edema due to ischemia. While decompressive hemicraniectomy (DC) improves outcome, many survivors experience lasting disabilities, and tools to predict outcome are lacking. We aimed to identify independent predictors of outcome following DC in MMI and to create a pragmatic, bedside tool for patient prognostication. This retrospective, multicenter study analyzed 318 MMI patients treated with DC at 4 Swedish university hospitals (2008-2022). Demographic, preoperative, and postoperative variables were collected from medical records. Six-month modified Rankin Scale (mRS) was the primary endpoint, with favorable outcome defined as mRS 0-3. Univariable and multivariable ordinal logistic regressions were employed to identify independent predictors of mRS. Significant independent preoperative variables were included in the malignant middle cerebral artery infarction DC (MAD) score. Median age was 56 (interquartile range: 48-61) years; 75% were male. At 6 months, median mRS was 4 (4-5), 24% achieved favorable outcome, and 17% were deceased. MAD score assigned 1 point to each independent preoperative predictor of worse outcome: higher age (≥ 60 years), female sex, lower Glasgow Coma Scale Motor score (< 4), and impaired pupillary reactivity (all P ≤ 0.03). MAD-stratified outcome, ordered from 0 to 4 points, was 32%, 25%, 15%, 0%, and 0% (favorable outcome) and 9%, 16%, 23%, 40%, and 100% (mortality). A large proportion of MMI patients recover unfavorably following DC. The presented MAD score was an internally reliable prognostic tool for MMI patients treated with DC. External validity of MAD and predictive value of female sex should be further explored.